X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2735) 2735
Publication (168) 168
Newsletter (125) 125
Book Review (50) 50
Newspaper Article (47) 47
Magazine Article (13) 13
Transcript (7) 7
Book Chapter (5) 5
Trade Publication Article (3) 3
Conference Proceeding (2) 2
Government Document (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
naproxen (1705) 1705
humans (1641) 1641
male (1139) 1139
female (1003) 1003
index medicus (861) 861
pharmacology & pharmacy (756) 756
adult (737) 737
naproxen - administration & dosage (687) 687
middle aged (658) 658
animals (570) 570
naproxen - therapeutic use (498) 498
aged (462) 462
anti-inflammatory agents, non-steroidal - administration & dosage (449) 449
anti-inflammatory agents, non-steroidal - adverse effects (421) 421
double-blind method (420) 420
nonsteroidal antiinflammatory drugs (417) 417
naproxen - adverse effects (414) 414
anti-inflammatory agents, non-steroidal - therapeutic use (382) 382
rats (345) 345
ibuprofen (328) 328
naproxen - pharmacology (327) 327
drugs (291) 291
nonsteroidal anti-inflammatory drugs (273) 273
treatment outcome (258) 258
analysis (244) 244
celecoxib (242) 242
pain (241) 241
adolescent (240) 240
osteoarthritis (238) 238
administration, oral (233) 233
dose-response relationship, drug (231) 231
time factors (220) 220
aspirin (214) 214
rheumatoid-arthritis (203) 203
drug therapy (201) 201
naproxen - chemistry (200) 200
anti-inflammatory agents, non-steroidal - pharmacology (198) 198
naproxen - pharmacokinetics (198) 198
medicine, general & internal (189) 189
double-blind (186) 186
research (183) 183
risk factors (179) 179
solubility (176) 176
dosage and administration (171) 171
care and treatment (170) 170
drug therapy, combination (170) 170
rofecoxib (165) 165
naproxen sodium (162) 162
diclofenac (157) 157
indomethacin (152) 152
pharmacokinetics (151) 151
inflammation (148) 148
arthritis, rheumatoid - drug therapy (147) 147
cox-2 inhibitors (145) 145
osteoarthritis - drug therapy (144) 144
efficacy (143) 143
rheumatology (141) 141
migraine (139) 139
nsaids (139) 139
risk (139) 139
analgesics (138) 138
chemistry, medicinal (136) 136
anti-inflammatory agents, non-steroidal - pharmacokinetics (132) 132
clinical neurology (132) 132
drug interactions (131) 131
drug administration schedule (130) 130
pain measurement (130) 130
anti-inflammatory agents, non-steroidal - chemistry (128) 128
arthritis (128) 128
clinical trials as topic (127) 127
clinical trials (126) 126
mice (119) 119
aged, 80 and over (116) 116
gastroenterology & hepatology (115) 115
rats, wistar (115) 115
cyclooxygenase inhibitors - adverse effects (113) 113
medicine & public health (111) 111
cyclooxygenase inhibitors - therapeutic use (110) 110
chemistry, multidisciplinary (107) 107
naproxen - blood (106) 106
pain - drug therapy (104) 104
gastrointestinal toxicity (103) 103
kinetics (101) 101
migraine disorders - drug therapy (101) 101
pharmaceutical industry (100) 100
acetaminophen (99) 99
rats, sprague-dawley (98) 98
cross-over studies (97) 97
prevention (96) 96
chemistry, analytical (95) 95
pharmacology (95) 95
pharmacology/toxicology (95) 95
young adult (95) 95
drug delivery systems (94) 94
ketoprofen (94) 94
placebo (94) 94
drug combinations (92) 92
sulfonamides - adverse effects (92) 92
anti-inflammatory drugs (91) 91
internal medicine (91) 91
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2819) 2819
German (29) 29
Italian (16) 16
Japanese (14) 14
French (12) 12
Spanish (11) 11
Russian (9) 9
Norwegian (8) 8
Polish (7) 7
Chinese (4) 4
Dutch (3) 3
Hungarian (3) 3
Danish (2) 2
Hebrew (2) 2
Swedish (2) 2
Turkish (2) 2
Czech (1) 1
Persian (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Pharmaceutics and Biopharmaceutics, ISSN 0939-6411, 2012, Volume 80, Issue 1, pp. 46 - 53
% Ketoprofen permeated after 300 min through the skin-simulating artificial membrane from hydrogel formulations loaded with drug alone or as co-ground product... 
Nanostructured lipid carriers (NLC) | Polymeric cyclodextrins | Hydrogel | Topical formulation | Ketoprofen | VIVO | NLC | NANOPARTICLES SLN | TRANSDERMAL DELIVERY | COMPLEXES | INDOMETHACIN | SOLID-STATE | IN-VITRO | BETA-CYCLODEXTRIN | PHARMACOLOGY & PHARMACY | NAPROXEN | Polymers - administration & dosage | Chemistry, Pharmaceutical - methods | Hydrogel, Polyethylene Glycol Dimethacrylate - chemistry | Drug Carriers - administration & dosage | Delayed-Action Preparations - chemistry | Drug Carriers - chemistry | Delayed-Action Preparations - administration & dosage | Ketoprofen - chemistry | Lipids - chemistry | Hydrogel, Polyethylene Glycol Dimethacrylate - administration & dosage | Cyclodextrins - chemistry | Epichlorohydrin - administration & dosage | Polysaccharides, Bacterial - chemistry | Polysaccharides, Bacterial - administration & dosage | Freeze Drying - methods | Drug Stability | Solubility | Ketoprofen - administration & dosage | Lipids - administration & dosage | Permeability | Particle Size | Epichlorohydrin - chemistry | beta-Cyclodextrins - administration & dosage | beta-Cyclodextrins - chemistry | Nanostructures - administration & dosage | Cyclodextrins - administration & dosage | Nanostructures - chemistry | Polymers - chemistry | Administration, Topical | Cyclodextrins | Dextrins | Transdermal medication
Journal Article
The American Journal of Medicine, ISSN 0002-9343, 2006, Volume 119, Issue 3, pp. 255 - 266
To evaluate the efficacy and upper gastrointestinal (UGI) safety of celecoxib, compared with nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs), among... 
Nonsteroidal anti-inflammatory agents | Cardiovascular events | Rofecoxib | Naproxen | Gastrointestinal events | NSAID gastropathy | Celecoxib | Osteoarthritis | Diclofenac | cardiovascular events | RHEUMATOID-ARTHRITIS | celecoxib | osteoarthritis | RANDOMIZED CONTROLLED-TRIAL | naproxen | rofecoxib | MEDICINE, GENERAL & INTERNAL | UPPER GASTROINTESTINAL TOXICITY | nonsteroidal anti-inflammatory agents | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | CLINICAL-TRIALS | ACUTE MYOCARDIAL-INFARCTION | ULCER COMPLICATIONS | COX-2 INHIBITORS | diclofenac | gastrointestinal events | Pyrazoles - therapeutic use | Humans | Middle Aged | Male | Osteoarthritis - drug therapy | Naproxen - administration & dosage | Female | Pyrazoles - adverse effects | Naproxen - adverse effects | Severity of Illness Index | Diclofenac - therapeutic use | Double-Blind Method | Drug Administration Schedule | Pain - classification | Diclofenac - adverse effects | Cyclooxygenase Inhibitors - administration & dosage | Naproxen - therapeutic use | Pyrazoles - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Sulfonamides - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Sulfonamides - adverse effects | Diclofenac - administration & dosage | Cyclooxygenase Inhibitors - adverse effects | Cyclooxygenase Inhibitors - therapeutic use | Osteoarthritis - classification | Sulfonamides - administration & dosage | Dosage and administration | Drug therapy
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10087, pp. 2375 - 2382
Summary Background Present guidelines are conflicting for patients at high risk of both cardiovascular and gastrointestinal events who continue to require... 
Internal Medicine | RHEUMATOID-ARTHRITIS | CYCLO-OXYGENASE-2 | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | PHARMACOLOGY | DICLOFENAC | PREVENTION | RISK | OSTEOARTHRITIS | Celecoxib - administration & dosage | Recurrence | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Secondary Prevention - methods | Aspirin - administration & dosage | Cyclooxygenase 2 Inhibitors - adverse effects | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Naproxen - administration & dosage | Cyclooxygenase 2 Inhibitors - therapeutic use | Peptic Ulcer Hemorrhage - prevention & control | Aged, 80 and over | Aspirin - therapeutic use | Drug Therapy, Combination | Celecoxib - adverse effects | Naproxen - adverse effects | Proton Pump Inhibitors - adverse effects | Double-Blind Method | Drug Administration Schedule | Cyclooxygenase 2 Inhibitors - administration & dosage | Peptic Ulcer Hemorrhage - chemically induced | Celecoxib - therapeutic use | Proton Pump Inhibitors - therapeutic use | Naproxen - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Arthritis - drug therapy | Aged | Care and treatment | Aspirin | Anti-inflammatory drugs | Gastrointestinal diseases | Naproxen | Clinical trials | Arthritis | Complications and side effects | Medical research | Gastrointestinal bleeding | Medicine, Experimental | Drugs | Funding | Risk | Population studies | Hemorrhage | Bleeding | Incidence | Prostaglandin endoperoxide synthase | Motivation | Safety | Nonsteroidal anti-inflammatory drugs | Antiinflammatory agents | Digestive system | Risk reduction | Inflammation | Celecoxib | Patients | Diseases | Omeprazole | Random numbers | Inhibitors | Ulcers | Healing | Fatalities | Cyclooxygenase-2 | Cardiovascular diseases | Health risk assessment
Journal Article
International Endodontic Journal, ISSN 0143-2885, 01/2012, Volume 45, Issue 1, pp. 76 - 82
Mehrvarzfar P, Abbott PV, Saghiri MA, Delvarani A, Asgar K, Lotfi M, Karamifar K, Kharazifard MJ, Khabazi H. Effects of three oral analgesics on postoperative... 
endodontics | pain | post‐instrumentation pain | NSAIDs | Post-instrumentation pain | Endodontics | Pain | TRAMADOL | MANAGEMENT | EFFICACY | PREVALENCE | VISIT ENDODONTIC THERAPY | COMBINATION | FLARE-UPS | IBUPROFEN | ACETAMINOPHEN | DENTISTRY, ORAL SURGERY & MEDICINE | DOUBLE-BLIND | post-instrumentation pain | Ibuprofen - therapeutic use | Caffeine - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Acetaminophen - administration & dosage | Male | Pulpitis - therapy | Young Adult | Caffeine - therapeutic use | Naproxen - administration & dosage | Placebos | Adult | Female | Acetaminophen - therapeutic use | Analgesics - therapeutic use | Double-Blind Method | Administration, Oral | Analgesics - administration & dosage | Analgesics, Opioid - therapeutic use | Ibuprofen - administration & dosage | Analgesics, Non-Narcotic - administration & dosage | Analgesics, Non-Narcotic - therapeutic use | Naproxen - therapeutic use | Pain, Postoperative - prevention & control | Tramadol - therapeutic use | Analgesics, Opioid - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Tramadol - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Pulpectomy - adverse effects | Root Canal Preparation - adverse effects | Pain Measurement | Drug Combinations | Care and treatment | Clinical trials | Pain, Postoperative | Dentifrices | Root canal therapy | Oral medication | Acetaminophen | Naproxen | Tramadol | Ibuprofen | Oral hygiene products | Dosage and administration | Universities and colleges | Public health | Caffeine
Journal Article
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, ISSN 1941-7705, 05/2009, Volume 2, Issue 3, pp. 155 - 163
Background-The cardiovascular safety of individual nonsteroidal antiinflammatory drugs (NSAIDs) is highly controversial, particularly in persons with serious... 
coxib | CARDIAC & CARDIOVASCULAR SYSTEMS | celecoxib | myocardial infarction | RANDOMIZED CONTROLLED-TRIAL | CYCLOOXYGENASE | CARE | naproxen | ELDERLY PERSONS | rofecoxib | coronary disease | antiinflammatory agents, nonsteroidal | COLORECTAL-CANCER | SASKATCHEWAN | ACUTE MYOCARDIAL-INFARCTION | SUDDEN CARDIAC DEATH | INHIBITORS | diclofenac | VALIDITY | Myocardial Infarction - mortality | Follow-Up Studies | Humans | Middle Aged | Sulfones - adverse effects | Male | Incidence | Outpatients - statistics & numerical data | Cyclooxygenase 2 Inhibitors - adverse effects | Lactones - administration & dosage | Naproxen - administration & dosage | Cardiovascular Diseases - mortality | Female | Retrospective Studies | Stroke - mortality | Pyrazoles - adverse effects | Naproxen - adverse effects | Diclofenac - adverse effects | Cyclooxygenase 2 Inhibitors - administration & dosage | Risk Factors | Ibuprofen - administration & dosage | Hospitalization | Celecoxib | Coronary Artery Disease - mortality | Lactones - adverse effects | Tennessee - epidemiology | Pyrazoles - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Sulfonamides - adverse effects | Aged | Ibuprofen - adverse effects | Diclofenac - administration & dosage | Sulfonamides - administration & dosage | Cohort Studies | Sulfones - administration & dosage
Journal Article
SCIENTIFIC REPORTS, ISSN 2045-2322, 08/2019, Volume 9, Issue 1, pp. 11160 - 11
Inflammatory conditions of the temporomandibular joint (TMJ) and peripheral tissues affect many people around the world and are commonly treated with... 
NANOPARTICLES | SODIUM | NANOSTRUCTURED LIPID CARRIERS | STABILITY | LIDOCAINE | MULTIDISCIPLINARY SCIENCES | IN-VIVO | SYSTEMS | TOPICAL DELIVERY | NATURAL LIPIDS | Nanoparticles | Pain perception | Leukocyte migration | Naproxen | Temporomandibular joint | Inflammation | Tumor necrosis factor-α | Nonsteroidal anti-inflammatory drugs | Joint diseases | IL-1β
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9736, pp. 173 - 179
Summary Background Cyclo-oxygenase (COX)-2-selective non-steroidal anti-inflammatory drugs (NSAIDs) and non-selective NSAIDs plus a proton-pump inhibitor (PPI)... 
Internal Medicine | GASTROINTESTINAL TOXICITY | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | MUCOSAL INJURY | OARSI RECOMMENDATIONS | RISK | NAPROXEN | PLUS OMEPRAZOLE | KNEE OSTEOARTHRITIS | EVIDENCE-BASED RECOMMENDATIONS | Lower Gastrointestinal Tract - drug effects | Osteoarthritis - ethnology | Humans | Middle Aged | Peptic Ulcer - prevention & control | Male | Osteoarthritis - drug therapy | Cyclooxygenase 2 Inhibitors - adverse effects | Arthritis, Rheumatoid - drug therapy | Adult | Female | Drug Therapy, Combination | Pyrazoles - adverse effects | Anti-Ulcer Agents - therapeutic use | Omeprazole - therapeutic use | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Diclofenac - adverse effects | Risk Factors | Treatment Outcome | Celecoxib | Pyrazoles - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Upper Gastrointestinal Tract - drug effects | Arthritis, Rheumatoid - ethnology | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Sulfonamides - adverse effects | Diclofenac - administration & dosage | Peptic Ulcer - chemically induced | Research Design | Sulfonamides - administration & dosage | Omeprazole | Rheumatoid arthritis | Dosage and administration | Research | Comparative analysis | Drug therapy | Diclofenac | Heart failure | Likert scale | Inflammatory bowel disease | Arthritis | Clinical medicine
Journal Article